Table 1 Characteristics of JIA patients and their peers at first documentation and 2-year follow-up
Variables | First documentation | 2-year follow-up | ||
|---|---|---|---|---|
| Â | JIA | Peers | JIA | Peers |
No. of patients | 214 | 141 | 214 | 141 |
Age, years | 14.4 ± 0.9 | 14.5 ± 1.0 | 16.4 ± 0.9 | 16.5 ± 1.0 |
BMI, kg/m² | 21.1 ± 3.5 | 20.9 ± 3.4 | 21.6 ± 3.9 | 21.4 ± 3.3 |
Female, no. (%) | 135 (63.1) | 77 (54.6) | 135 (63.1) | 77 (54.6) |
Disease duration, years | 2.6 ± 2.0 |  | 4.7 ± 2.0 |  |
JIA category, no. (%) | Â | Â | Â | Â |
 RF-positive polyarthritis | 10 (4.8) |  | 10 (4.8) |  |
 RF-negative polyarthritis | 59 (28.1) |  | 59 (28.1) |  |
 Systemic JIA | 6 (2.9) |  | 6 (2.9) |  |
 Persistent oligoarthritis | 37 (17.6) |  | 37 (17.6) |  |
 Extended oligoarthritis | 18 (8.6) |  | 18 (8.6) |  |
 Psoriatic arthritis | 18 (8.6) |  | 18 (8.6) |  |
 Enthesitis-related arthritis | 44 (21.0) |  | 44 (21.0) |  |
 Unclassified JIA | 18 (8.6) |  | 18 (8.6) |  |
cJADAS-10, mean (SD) | 6.1 ± 6.0 |  | 3.1 ± 3.8 |  |
PGA score (NRS 0–10), mean (SD) | 1.85 ± 2.3 |  | 0.7 ± 1.3 |  |
Inactive disease, no. (%) | 63 (35.4) | Â | 93 (56.4) | Â |
No. of active joints | 2.1 ± 4.2 |  | 0.7 ± 1.8 |  |
Patient-reported data | Â | Â | Â | Â |
 C-HAQ total score, mean (SD) | 0.3 ± 0.5 |  | 0.2 ± 3.9 |  |
 No functional limitations*, no. (%) | 104 (50.0) |  | 134 (65.0) |  |
 Overall well-being (NRS 0–10), mean (SD) | 2.1 ± 2.3 | 1.0 ± 1.4 | 1.5 ± 2.0 | 1.0 ± 1.2 |
 Pain intensity (NRS 0–10), mean (SD) | 2.1 ± 2.5 | 1.0 ± 1.5 | 1.4 ± 1.9 | 1.2 ± 1.8 |
 PedsQL total score, mean (SD) | 84.5 ± 16.3 | 91.4 ± 7.8 | 89.6 ± 13.2 | 91.2 ± 8.5 |
 PedsQL physical health, mean (SD) | 80.7 ± 21.7 | 93.5 ± 9.3 | 87.9 ± 17.2 | 93.0 ± 8.9 |
 PedsQL psychosocial health, mean (SD) | 86.5 ± 15.4 | 90.3 ± 8.7 | 90.4 ± 12.7 | 90.3 ± 9.7 |
 Low/medium SES | 171 (81.4) | 90 (63.8) | 171 (81,4) | 90 (63.8) |
 High SES | 39 (18.6) | 51 (36.2) | 39 (18.6) | 51 (36.2) |
Current treatment, no. (%) | Â | Â | Â | Â |
 Any DMARD | 95 (52.2) |  | 97 (58.8) |  |
 Any conventional synthetic DMARD | 75 (41.2) |  | 61 (37.0) |  |
 Any biologic DMARD | 39 (21.4) |  | 63 (38.2) |  |
 NSAIDs | 79 (43.4) |  | 31 (18.8) |  |
 Systemic GCs | 30 (16.5) |  | 11 (6.7) |  |